Article Text

PDF
162
VSN16R – A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS
  1. Thomas Williams1,
  2. Gareth Pryce2,
  3. Gavin Giovannoni2,
  4. David Selwood3,
  5. David Baker2
  1. 1 UCLH
  2. 2 Queen Mary University of London
  3. 3 UCL Wolfson Institute for Biomedical Research

Abstract

Current symptomatic treatments for spasticity in multiple sclerosis often exhibit intolerable side-effects that limit their use. We synthesized a novel compound, VSN16R, which exhibited anti-spastic activity in experimental autoimmune encephalomyelitis (EAE) in mice and was as active as baclofen and cannabinoids but lacked their sedative side-effects. The drug was found to be a novel, potent BKCa calcium activated potassium channel modulator in vitro. VSN16R was orally active and remarkably well-tolerated, with over a thousand fold therapeutic window, and demonstrated no obvious adverse neurobehavioural effects in mice. It was also well tolerated in other larger animal species and importantly in humans, where phase 1 studies found VSN16R to produced high oral bioavailability and no serious adverse behavioural or physiological events at supra-therapeutic plasma concentrations. VSN16R has the potential to inhibit pathogenic spinal cord hyperreflexia and can drive neuronal potassium-induced hyperpolarisation to limit spasticity via BKCa opening. This study identifies a novel target for control of spasticity and suggests that VSN16R may be a useful novel therapeutic, which offers tolerability advantages over existing treatments. This may facilitate adoption of earlier treatment following to development of spasticity in MS. A phase II clinical trial (NCT02542787) is currently in progress.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.